Chemical Compound Review:
AKOS005430103 2-hydroxy-3-(3-oxo-1-phenyl- butyl)chromen...
Synonyms:
Orsinelli,
Erbel,
Asinger,
Kistler,
Li,
Murray,
Anand,
Pettigrew,
A.E. Rettie,
Porter,
Fan,
Yusuf,
Israels,
Sudlow,
Trauner,
Newman,
Apperson-Hansen,
Halperin,
Mark Blostein,
Eccles,
Levin,
Pogue,
Jackson,
Grimm,
Thomson,
Romano,
Albers,
Klein,
Israels,
Schulman,
Black,
Sacco,
Pullicino,
Susan R. Kahn,
Adams,
Thompson,
Robinson,
Gettner,
Parkin,
Jean-Paul Collet,
James A. Hanley,
Flather,
A.P. Reiner,
M.J. Rieder,
Furie,
Mohr,
White,
Vicky Tagalakis,
Saxena,
Stoddard,
Lazar,
Lindmarker,
Davidoff,
Weitz,
Hani Tamim,
- Randomized trials of warfarin for atrial fibrillation. Singer, D.E. N. Engl. J. Med. (1992)
- The management of thrombosis in the antiphospholipid-antibody syndrome. Khamashta, M.A., Cuadrado, M.J., Mujic, F., Taub, N.A., Hunt, B.J., Hughes, G.R. N. Engl. J. Med. (1995)
- Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. Schulman, S., Lindmarker, P. N. Engl. J. Med. (2000)
- A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. Hull, R., Raskob, G., Pineo, G., Rosenbloom, D., Evans, W., Mallory, T., Anquist, K., Smith, F., Hughes, G., Green, D. N. Engl. J. Med. (1993)
- A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. Mohr, J.P., Thompson, J.L., Lazar, R.M., Levin, B., Sacco, R.L., Furie, K.L., Kistler, J.P., Albers, G.W., Pettigrew, L.C., Adams, H.P., Jackson, C.M., Pullicino, P. N. Engl. J. Med. (2001)
- Use of warfarin and risk of urogenital cancer: a population-based, nested case-control study. Tagalakis, V., Tamim, H., Blostein, M., Collet, J.P., Hanley, J.A., Kahn, S.R. Lancet Oncol. (2007)
- Risk of thromboembolism with short-term interruption of warfarin therapy. Garcia, D.A., Regan, S., Henault, L.E., Upadhyay, A., Baker, J., Othman, M., Hylek, E.M. Arch. Intern. Med. (2008)
- Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Ezekowitz, M.D., Bridgers, S.L., James, K.E., Carliner, N.H., Colling, C.L., Gornick, C.C., Krause-Steinrauf, H., Kurtzke, J.F., Nazarian, S.M., Radford, M.J. N. Engl. J. Med. (1992)
- Acetaminophen and other risk factors for excessive warfarin anticoagulation. Hylek, E.M., Heiman, H., Skates, S.J., Sheehan, M.A., Singer, D.E. JAMA (1998)
- Decision analysis and guidelines for anticoagulant therapy to prevent stroke in patients with atrial fibrillation. Thomson, R., Parkin, D., Eccles, M., Sudlow, M., Robinson, A. Lancet (2000)
- Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: organization to assess strategies for ischemic syndromes (OASIS) pilot study results. Anand, S.S., Yusuf, S., Pogue, J., Weitz, J.I., Flather, M. Circulation (1998)
- Atrial fibrillation and stroke prevention with warfarin in the long-term care setting. Gurwitz, J.H., Monette, J., Rochon, P.A., Eckler, M.A., Avorn, J. Arch. Intern. Med. (1997)
- Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. Klein, A.L., Grimm, R.A., Murray, R.D., Apperson-Hansen, C., Asinger, R.W., Black, I.W., Davidoff, R., Erbel, R., Halperin, J.L., Orsinelli, D.A., Porter, T.R., Stoddard, M.F. N. Engl. J. Med. (2001)
- A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. Leon, M.B., Baim, D.S., Popma, J.J., Gordon, P.C., Cutlip, D.E., Ho, K.K., Giambartolomei, A., Diver, D.J., Lasorda, D.M., Williams, D.O., Pocock, S.J., Kuntz, R.E. N. Engl. J. Med. (1998)
- Coexistence of hereditary homocystinuria and factor V Leiden--effect on thrombosis. Mandel, H., Brenner, B., Berant, M., Rosenberg, N., Lanir, N., Jakobs, C., Fowler, B., Seligsohn, U. N. Engl. J. Med. (1996)
- Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. Hull, R.D., Raskob, G.E., Rosenbloom, D., Panju, A.A., Brill-Edwards, P., Ginsberg, J.S., Hirsh, J., Martin, G.J., Green, D. N. Engl. J. Med. (1990)
- A cluster of sulfatase genes on Xp22.3: mutations in chondrodysplasia punctata (CDPX) and implications for warfarin embryopathy. Franco, B., Meroni, G., Parenti, G., Levilliers, J., Bernard, L., Gebbia, M., Cox, L., Maroteaux, P., Sheffield, L., Rappold, G.A. Cell (1995)
- Influenza vaccination and warfarin or theophylline toxicity in nursing-home residents. Patriarca, P.A., Kendal, A.P., Stricof, R.L., Weber, J.A., Meissner, M.K., Dateno, B. N. Engl. J. Med. (1983)
- Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences. Rauch, U., Osende, J.I., Fuster, V., Badimon, J.J., Fayad, Z., Chesebro, J.H. Ann. Intern. Med. (2001)
- Racemic warfarin and trimethoprim-sulfamethoxazole interaction in humans. O'Reilly, R.A., Motley, C.H. Ann. Intern. Med. (1979)
- Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. Higashi, M.K., Veenstra, D.L., Kondo, L.M., Wittkowsky, A.K., Srinouanprachanh, S.L., Farin, F.M., Rettie, A.E. JAMA (2002)
- Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Study No. 75. Zacharski, L.R., Henderson, W.G., Rickles, F.R., Forman, W.B., Cornell, C.J., Forcier, R.J., Edwards, R., Headley, E., Kim, S.H., O'Donnell, J.R., O'Dell, R., Tornyos, K., Kwaan, H.C. JAMA (1981)
- Effects of sodium warfarin and sodium heparin plus anticancer agents on growth of rat C6 glioma cells. McNiel, N.O., Morgan, L.R. J. Natl. Cancer Inst. (1984)
- A novel role for vitamin K1 in a tyrosine phosphorylation cascade during chick embryogenesis. Saxena, S.P., Fan, T., Li, M., Israels, E.D., Israels, L.G. J. Clin. Invest. (1997)
- Sulphinpyrazone and warfarin: a probable drug interaction. Gallus, A., Birkett, D. Lancet (1980)
- A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. Turpie, A.G., Gent, M., Laupacis, A., Latour, Y., Gunstensen, J., Basile, F., Klimek, M., Hirsh, J. N. Engl. J. Med. (1993)
- Delayed hypersensitivity in man: effects of systemic anticoagulation. Edwards, R.L., Rickles, F.R. Science (1978)
- Drug prophylaxis for arterial thromboembolism--1981. Wessler, S. JAMA (1981)
- Two-step warfarin therapy. Prevention of postoperative venous thrombosis without excessive bleeding. Francis, C.W., Marder, V.J., Evarts, C.M., Yaukoolbodi, S. JAMA (1983)
- Cardioversion from atrial fibrillation without prolonged anticoagulation with use of transesophageal echocardiography to exclude the presence of atrial thrombi. Manning, W.J., Silverman, D.I., Gordon, S.P., Krumholz, H.M., Douglas, P.S. N. Engl. J. Med. (1993)
- Prolongation of prothrombin time and severe gastrointestinal bleeding associated with combined use of warfarin and ketoprofen. Flessner, M.F., Knight, H. JAMA (1988)
- Vitamin K-dependent carboxylation and vitamin K metabolism in liver. Effects of warfarin. Wallin, R., Martin, L.F. J. Clin. Invest. (1985)
- Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. Marcu, M.G., Schulte, T.W., Neckers, L. J. Natl. Cancer Inst. (2000)
- A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. D'Andrea, G., D'Ambrosio, R.L., Di Perna, P., Chetta, M., Santacroce, R., Brancaccio, V., Grandone, E., Margaglione, M. Blood (2005)
- Biochemical and biological characterization of a novel anti-aromatase coumarin derivative. Chen, S., Cho, M., Karlsberg, K., Zhou, D., Yuan, Y.C. J. Biol. Chem. (2004)
- Gas6 induces Akt/mTOR-mediated mesangial hypertrophy in diabetic nephropathy. Nagai, K., Matsubara, T., Mima, A., Sumi, E., Kanamori, H., Iehara, N., Fukatsu, A., Yanagita, M., Nakano, T., Ishimoto, Y., Kita, T., Doi, T., Arai, H. Kidney Int. (2005)
- Identification by shotgun sequencing, genomic organization, and functional analysis of a fourth arylsulfatase gene (ARSF) from the Xp22.3 region. Puca, A.A., Zollo, M., Repetto, M., Andolfi, G., Guffanti, A., Simon, G., Ballabio, A., Franco, B. Genomics (1997)
- Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians. Schelleman, H., Chen, Z., Kealey, C., Whitehead, A.S., Christie, J., Price, M., Brensinger, C.M., Newcomb, C.W., Thorn, C.F., Samaha, F.F., Kimmel, S.E. Clin. Pharmacol. Ther. (2007)
- Gamma-glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose. Rieder, M.J., Reiner, A.P., Rettie, A.E. J. Thromb. Haemost. (2007)
- Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement. Kim, H.S., Lee, S.S., Oh, M., Jang, Y.J., Kim, E.Y., Han, I.Y., Cho, K.H., Shin, J.G. Pharmacogenet. Genomics (2009)
- Drugs and surgery in the prevention of ischemic stroke. Barnett, H.J., Eliasziw, M., Meldrum, H.E. N. Engl. J. Med. (1995)
- Predictors of rehospitalization for symptomatic venous thromboembolism after total hip arthroplasty. White, R.H., Gettner, S., Newman, J.M., Trauner, K.B., Romano, P.S. N. Engl. J. Med. (2000)
- A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. Kearon, C., Gent, M., Hirsh, J., Weitz, J., Kovacs, M.J., Anderson, D.R., Turpie, A.G., Green, D., Ginsberg, J.S., Wells, P., MacKinnon, B., Julian, J.A. N. Engl. J. Med. (1999)
- Low molecular weight heparin: a critical analysis of clinical trials. Green, D., Hirsh, J., Heit, J., Prins, M., Davidson, B., Lensing, A.W. Pharmacol. Rev. (1994)
- Calcification inside artificial hearts: inhibition by warfarin-sodium. Pierce, W.S., Donachy, J.H., Rosenberg, G., Baier, R.E. Science (1980)